title: d-Cycloserine administration does not affect neurocognition in concurrent cocaine- and nicotine-dependent volunteers.
abstract: Neurocognitive impairment is a well-documented consequence of long-term, repeated cocaine exposure and has been identified as an important target of treatment. Thus, this study sought to determine whether the N-methyl-d-aspartate (NMDA) partial agonist, d-cycloserine could improve neurocognitive performance in a sample of 27 long-term, high dose cocaine dependent individuals who were not seeking treatment at the time of enrollment in the study. This double-blind, placebo-controlled study evaluated whether a single dose of 0 or 50mg of d-cycloserine would enhance performance on measures of attention/information processing speed, episodic memory, and executive/frontal lobe functioning relative to test performance at baseline. The results revealed that d-cycloserine did not modulate neurocognition in this cohort, though there are a number of factors that may have mitigated the effects of d-cycloserine in this particular study. The negative findings notwithstanding, the current study serves as a springboard for future investigations that will examine whether other medications that can modulate neurocognition in cocaine-dependent study participants.
authors.affiliation: Baylor College of Medicine, Menninger Department of Psychiatry and Behavioral Sciences, Houston, TX 77030, United States. kalechst@bcm.edu
authors.forename: A D
authors.initials: AD
authors.lastname: Kalechstein
authors.forename: J H
authors.initials: JH
authors.lastname: Yoon
authors.forename: J J
authors.initials: JJ
authors.lastname: Mahoney
authors.forename: T F
authors.initials: TF
authors.lastname: Newton
authors.forename: L
authors.initials: L
authors.lastname: Chang
authors.forename: R
authors.initials: R
authors.lastname: De La Garza
mesh_terms: D019970:Cocaine-Related Disorders / Q000523:psychology*; D003071:Cognition / Q000187:drug effects*; D003523:Cycloserine / Q000008:administration & dosage* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009538:Nicotine / Q000009:adverse effects*; D010919:Placebos
chemical_list: D010919:Placebos; D009538:Nicotine; D003523:Cycloserine